Key result
Oral anticoagulants prevent recurrent thromboembolism, whereas inadequate therapy carries up to ~25% recurrence risk.
Why the study?
Patients with venous thromboembolic disease require effective treatment to stop thrombosis and prevent recurrence, but prolonged oral anticoagulant therapy carries bleeding risks.
Patients with venous thromboembolic disease require treatment to stop the thrombotic process. The importance of immediate therapy with parenteral anticoagulants or thrombolytic agents (or both) is unquestioned.1,2 Furthermore, several well-designed clinical trials have demonstrated that oral anticoagulant therapy with warfarin derivatives prevents the development of recurrent thromboembolic disease,36 whereas inadequate anticoagulant therapy carries a risk of recurrent thromboembolism that can be as high as 25 percent.5 These studies also show that prolonged anticoagulant therapy is associated with an increased risk of bleeding.36 This risk can be lessened, but not eliminated, by appropriate monitoring of warfarin therapy.7, . . .
No takes yet. Share an insight, caveat, or question.
David L. Diuguid (1997) conducted a review in Venous thromboembolic disease. Oral anticoagulant therapy with warfarin derivatives vs. Inadequate anticoagulant therapy was evaluated on Recurrent thromboembolic disease. Oral anticoagulant therapy with warfarin derivatives prevents recurrent thromboembolic disease, whereas inadequate therapy carries a recurrence risk up to 25%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: